CD70 limits atherosclerosis and promotes macrophage function

Summary

The costimulatory molecule CD70 is expressed on activated immune cells and is known to modulate responses of T, B, and NK cells via its receptor CD27. Until now, there is only limited data describing the role of CD70 in atherosclerosis. We observed that ruptured human carotid atherosclerotic plaques displayed higher CD70 expression than stable carotid atherosclerotic plaques, and that CD70 expression in murine atheroma localized to macrophages. Lack of CD70 impaired the inflammatory capacity (e. g. reactive oxygen species and nitric oxide production) of bone marrow-derived macrophages, increased both M1-like and M2-like macrophage markers, and rendered macrophages meta-bolically inactive and prone to apoptosis. Moreover, CD70-deficient macrophages expressed diminished levels of scavenger receptors and ABC-transporters, impairing uptake of oxidised low-density lipoprotein (oxLDL) and cholesterol efflux, respectively. Hyperlipidaemic Apoe ^−/− mice reconstituted with CD70-deficient bone marrow displayed a profound increase in necrotic core size, plaque area, and number of lesional macrophages as compared to mice receiving control bone marrow. Accordingly, 18 week-old, chow diet-fed CD70-deficient Apoe^−/−mice displayed larger atheroma characterised by lower cellularity and more advanced plaque phenotype than Apoe^−/− mice. In conclusion, CD70 promotes macrophage function and viability and is crucial for effective phagocytosis and efflux of oxLDL. Deficiency in CD70 results in more advanced atheroma. Our data suggest that CD70 mitigates atherosclerosis at least in part by modulating macrophage function.

Note: The review process for this manuscript was fully handled by G. Y. H. Lip, Editor in Chief.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Atherosclerosis - inflammation - macrophages - CD70

• References

• 1 McWilliams JA, Sanchez PJ, Haluszczak C. et al. Multiple innate signalling pathways cooperate with cd40 to induce potent, cd70-dependent cellular immunity. Vaccine 2010; 28: 1468-1476.
• 2 Tesselaar K, Xiao Y, Arens R. et al. Expression of the murine cd27 ligand cd70 in vitro and in vivo. J. Immunol 2003; 170: 33-40.
• 3 Coquet JM, Ribot JC, Babala N. et al. Epithelial and dendritic cells in the thymic medulla promote cd4+foxp3+ regulatory t cell development via the cd27-cd70 pathway. J Exp Med 2013; 210: 715-728.
• 4 Sanchez PJ, McWilliams JA, Haluszczak C. et al. Combined tlr/cd40 stimulation mediates potent cellular immunity by regulating dendritic cell expression of cd70 in vivo. J Immunol 2007; 178: 1564-1572.
• 5 Hendriks J, Gravestein LA, Tesselaar K. et al. Cd27 is required for generation and long-term maintenance of t cell immunity. Nature Immunol 2000; 01: 433-440.
• 6 Nolte MA, van Olffen RW, van Gisbergen KP, van Lier RA. Timing and tuning of cd27-cd70 interactions: The impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009; 229: 216-231.
• 7 Borst J, Hendriks J, Xiao Y. Cd27 and cd70 in t cell and b cell activation. Curr Opin Immunol 2005; 17: 275-281.
• 8 van Oosterwijk MF, Juwana H, Arens R. et al. Cd27-cd70 interactions sensitise naive cd4+ t cells for il-12-induced th1 cell development. Intern Immunol 2007; 19: 713-718.
• 9 Peperzak V, Veraar EA, Keller AM. et al. The pim kinase pathway contributes to survival signalling in primed cd8+ t cells upon cd27 costimulation. J Immunol 2010; 185: 6670-6678.
• 10 Peperzak V, Xiao Y, Veraar EA, Borst J. Cd27 sustains survival of ctls in virus-infected nonlymphoid tissue in mice by inducing autocrine il-2 production. J Clin Invest 2010; 120: 168-178.
• 11 van de Ven K, Borst J. Targeting the t-cell costimulatory cd27/cd70 pathway in cancer immunotherapy: Rationale and potential. Immunotherapy 2015; 07: 655-667.
• 12 Manocha M, Rietdijk S, Laouar A. et al. Blocking cd27-cd70 costimulatory pathway suppresses experimental colitis. J Immunol 2009; 183: 270-276.
• 13 Coquet JM, Middendorp S, van der Horst G. et al. The cd27 and cd70 costimulatory pathway inhibits effector function of t helper 17 cells and attenuates associated autoimmunity. Immunity 2013; 38: 53-65.
• 14 Shaw J, Wang YH, Ito T. et al. Plasmacytoid dendritic cells regulate b-cell growth and differentiation via cd70. Blood 2010; 115: 3051-3057.
• 15 de Boer OJ, Hirsch F, van der Wal AC. et al. Costimulatory molecules in human atherosclerotic plaques: An indication of antigen specific t lymphocyte activation. Atherosclerosis 1997; 133: 227-234.
• 16 van Olffen RW, de Bruin AM, Vos M. et al. Cd70-driven chronic immune activation is protective against atherosclerosis. Journal of innate immunity 2010; 02: 344-352.
• 17 Stoger JL, Gijbels MJ, van der Velden S. et al. Distribution of macrophage polarisation markers in human atherosclerosis. Atherosclerosis 2012; 225: 461-468.
• 18 Hoeksema MA, Gijbels MJ, Van den Bossche J. et al. Targeting macrophage histone deacetylase 3 stabilizes atherosclerotic lesions. EMBO Mol Med 2014; 06: 1124-1132.
• 19 Virmani R, Kolodgie FD, Burke AP. et al. Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-1275.
• 20 Koltsova EK, Garcia Z, Chodaczek G. et al. Dynamic t cell-apc interactions sustain chronic inflammation in atherosclerosis. J Clin Invest 2012; 122: 3114-3126.
• 21 Van den Bossche J, Baardman J, de Winther MP. Metabolic characterisation of polarized m1 and m2 bone marrow-derived macrophages using real-time extracellular flux analysis. J Visualized Exp 2015 Epub ahead of print
• 22 Yvan-Charvet L, Wang N, Tall AR. Role of hdl, abca1, and abcg1 transporters in cholesterol efflux and immune responses. Arterioscl Thromb Vasc Biol 2010; 30: 139-143.
• 23 Covarrubias A, Byles V, Horng T. Ros sets the stage for macrophage differentiation. Cell Res 2013; 23: 984-985.
• 24 O’Neill LA, Hardie DG. Metabolism of inflammation limited by ampk and pseudo-starvation. Nature 2013; 493: 346-355.
• 25 Freemerman AJ, Johnson AR, Sacks GN. et al. Metabolic reprogramming of macrophages: Glucose transporter 1 (glut1)-mediated glucose metabolism drives a proinflammatory phenotype. J Biol Chem 2014; 289: 7884-7896.
• 26 Tannahill GM, Curtis AM, Adamik J. et al. Succinate is an inflammatory signal that induces il-1beta through hif-1alpha. Nature 2013; 496: 238-242.
• 27 Huang SC, Everts B, Ivanova Y. et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages. Nature Immunol 2014; 15: 846-855.
• 28 Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: A dynamic balance. Nature Rev Immunol 2013; 13: 709-721.
• 29 Arens R, Nolte MA, Tesselaar K. et al. Signalling through cd70 regulates b cell activation and igg production. J Immunol 2004; 173: 3901-3908.
• 30 Huang J, Jochems C, Anderson AM. et al. Soluble cd27-pool in humans may contribute to t cell activation and tumor immunity. J Immunol 2013; 190: 6250-6258.
• 31 Cochain C, Koch M, Chaudhari SM. et al. Cd8+ t cells regulate monopoiesis and circulating ly6c–high monocyte levels in atherosclerosis in mice. Circulation Res 2015; 117: 244-253.
• 32 Kyaw T, Winship A, Tay C. et al. Cytotoxic and proinflammatory cd8+ t lymphocytes promote development of vulnerable atherosclerotic plaques in apoe-deficient mice. Circulation 2013; 127: 1028-1039.
• 33 Diegmann J, Junker K, Gerstmayer B. et al. Identification of cd70 as a diagnostic biomarker for clear cell renal cell carcinoma by gene expression profiling, realtime rt-pcr and immunohistochemistry. Eur J Cancer 2005; 41: 1794-1801.
• 34 Junker K, Hindermann W, von Eggeling F. et al. Cd70: A new tumor specific biomarker for renal cell carcinoma. The Journal of urology 2005; 173: 2150-2153.
• 35 Ryan MC, Kostner H, Gordon KA. et al. Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-cd70 antibody-drug conjugate sgn-75. Br J Cancer 2010; 103: 676-684.
• 36 Wischhusen J, Jung G, Radovanovic I. et al. Identification of cd70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. Cancer Res 2002; 62: 2592-2599.
• 37 Trebing J, El-Mesery M, Schafer V. et al. Cd70-restricted specific activation of trailr1 or trailr2 using scfv-targeted trail mutants. Cell Death Dis 2014; 05: e1035.
• 38 Yang ZZ, Grote DM, Xiu B. et al. Tgf-beta upregulates cd70 expression and induces exhaustion of effector memory t cells in b-cell non-hodgkin’s lymphoma. Leukemia 2014; 28: 1872-1884.
• 39 Grewal IS. Cd70 as a therapeutic target in human malignancies. Exp Opin Therap Targets 2008; 12: 341-351.
• 40 https://clinicaltrials.gov/ct2/results?term=cd70+tumor&Search=Search